SAB4200772
Anti-BRAF (V600E) antibody produced in rabbit
affinity isolated antibody
Synonym(s):
Anti-Proto-oncogene B-Raf, p94, Anti-Serine/threonine-protein kinase B-raf, Anti-v-Raf murine sarcoma viral oncogene homolog B1
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.44
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
—
Citations:
11
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
~95 kDa
species reactivity
human
enhanced validation
recombinant expression
Learn more about Antibody Enhanced Validation
concentration
~1 mg/mL
technique(s)
immunoblotting: 2-4 μg/mL using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... BRAF(673)
General description
B-Raf proto-oncogene serine/threonine-protein kinase (BRAF), also known as Serine/threonine-protein kinase B-raf, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1, is a member of the RAF family. BRAF is one of the key factors in mitogen-activated protein kinase (MAPK) signaling pathway, which is activated by members of the Ras family upon growth factor-induced stimulation. BRAF controls and regulates numerous essential cellular mechanisms including cell proliferation, differentiation, development, survival, apoptosis and secretion.1-2 In contrast to the majority of oncogenic fusion kinases such as ALK, ROS1, NTRK1 and RET that are receptor tyrosine kinases, BRAF encodes a non-receptor serine/threonine kinase, placing its normal protein localization within the cytoplasm rather than associated with the plasma membrane.3
BRAF is mutated at a high frequency in several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, nonsmall cell lung carcinoma, and adenocarcinoma of lung.
BRAF is mutated at a high frequency in several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, nonsmall cell lung carcinoma, and adenocarcinoma of lung.
Immunogen
Synthetic peptide from the C-terminal region of human BRAF protein, conjugated to KLH
Application
Immunoblotting: a working concentration of 2-4 g/mL is recommended using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein.
Biochem/physiol Actions
Anti-BRAF (V600E) recognizes V600E mutated human BRAF protein. The antibody may be used in various immunochemical techniques including Immunoblotting.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Nourah Mohammad Obaid et al.
International journal of molecular sciences, 18(3) (2017-03-12)
The development of resistance to previously effective treatments has been a challenge for health care providers and a fear for patients undergoing cancer therapy. This is an unfortunately frequent occurrence for patients undergoing targeted therapy for tumours harboring the activating
Roland Houben et al.
Journal of carcinogenesis, 3, 6-6 (2004-03-30)
Genes of the Raf family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Recently, it was shown that activating mutations of BRaf are found with high frequency in human melanomas. The Ras family member
Nicolas Stransky et al.
Nature communications, 5, 4846-4846 (2014-09-11)
Human cancer genomes harbour a variety of alterations leading to the deregulation of key pathways in tumour cells. The genomic characterization of tumours has uncovered numerous genes recurrently mutated, deleted or amplified, but gene fusions have not been characterized as
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SAB4200772-100UL | 04061833265284 |